As of November 6, 2026, Coya Therapeutics, Inc. is a publicly traded company (Nasdaq: COYA); its largest reported holder is Dr. Reddy's Laboratories, Inc., with 9.7% on Schedule 13G of March 12, 2026. The largest insider holding is Dov Goldstein, a director, with 27,557 shares (0.12% of shares outstanding), per Form 4 of August 19, 2025 (Schedule 13G, March 12, 2026).
Is this your company?
About to sign with, pay or invest in Coya Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Coya Therapeutics, Inc. a real, registered company?
- Coya Therapeutics, Inc. files with the SEC under CIK 1835022 (its SEC filings).
- Its shares are listed under the ticker COYA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Houston, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Coya Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Mark H. Pavao (Form 8-K filed 2026-08-07). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Dr. Reddy's Laboratories, Inc. (filed 2026-03-12).
Who are Coya Therapeutics, Inc.'s owners and officers?
Coya Therapeutics, Inc.: incorporated in Delaware; business address in Houston, Texas; industry Pharmaceutical Preparations (Form D, 2026-08-07).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-10-28)
- : Executive Officer (Form D, 2024-10-28)
- : Executive Officer (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
- : Director (Form D, 2024-10-28)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-07-27 | Orin Hirschman | 3.3% |
| Schedule 13G, 2026-03-12 | Dr. Reddy'S Laboratories, Inc. | 9.7% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 4.29% |
| Schedule 13G/A, 2026-01-28 | Orin Hirschman | 5.3% |
Questions about who owns Coya Therapeutics, Inc.
Who owns Coya Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Coya Therapeutics, Inc.: Dr. Reddy'S Laboratories, Inc. (9.7%, Schedule 13G, filed 2026-03-12).
When did Dr. Reddy'S Laboratories, Inc. buy into Coya Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Reddy'S Laboratories, Inc. on this page is the Schedule 13G, filed 2026-03-12, reporting 9.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Coya Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Coya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Coya Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-07 | Mark H. Pavao | appointed | ||
| Form 8-K, 2026-04-02 | Howard Berman | Executive Chairman | departed | 2026-04-01 |
| Form 8-K, 2026-04-02 | Mark H. Pavao | Director | appointed | 2026-04-01 |
Which insiders own Coya Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 27,557 shares (0.12% of shares outstanding) (Form 4, 2025-08-19).
- , the chief executive and a director: 10,000 shares (0.04% of shares outstanding) (Form 4, 2024-11-13).
- , the chief financial officer: 8,800 shares (0.04% of shares outstanding) (Form 4, 2024-11-14).
- , the chief medical officer: 2,710 shares (0.01% of shares outstanding) (Form 4, 2024-11-12).
Shares outstanding: 23,457,849 as of 2026-08-07, from the company's latest SEC cover page.
How much has Coya Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-10-28 | $10M | $10M |
| Form D, 2023-12-20 | $26.48M | $26.48M |
Keep reading
More on Coya Therapeutics, Inc. and the records around it.
Coya Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- 5%+ stake filings Jul 2026
Companies that share a holder
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/coya-therapeutics